Drug Profile
Research programme: RNA interference-based therapeutics - Intradigm/Sequitur
Alternative Names: RNA interference-based therapeutics research programme - Intradigm; RNAi-based therapeutics research programme - IntradigmLatest Information Update: 14 Jul 2010
Price :
$50
*
At a glance
- Originator Intradigm Corporation; Sequitur
- Developer Silence Therapeutics
- Class RNA
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Dec 2003 Sequitur has been acquired by Invitrogen Corporation
- 24 Jun 2003 Intradigm and Sequitur have entered into an agreement to co-promote and co-develop RNAi-based therapeutics in the USA for diseases including cancer
- 27 Aug 2002 Preclinical trials in Cancer in USA (unspecified route)